Disease Modifying Therapies for Chronic Lung Disease (R61/R33 Clinical Trial Required)
Department of Health and Human Services National Institutes of Health
Posted on:
Bewerbungsschluss:
Expired
Typ
Research/project funding
Reference Number
RFA-HL-21-013
The purpose of this Funding Opportunity Announcement (FOA) is to support multiple Protocol Leadership Groups (PLGs) that will conduct phase II trials within the NHLBI Pulmonary Trials Cooperative (PTC) clinical trials network. The PTC will include multiple Protocol Leadership Groups (PLGs) and a single Network Management Core (NEMO) and will conduct multiple simultaneous phase II clinical trials that test innovative disease modifying therapies (DMT) for chronic lung diseases.
Categories: Health.
Categories: Health.
USA